Yarrow Bioscience grants Payton 99,827 stock options

The options have an expiration date of October 29, 2036.

Available on EDGAR 10/30/2026 - 04:05 PM EDT Accepted by SEC EDGAR 10/30/2026 - 04:04 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Yarrow Bioscience, Inc. (YARW) Chief Development Officer Lori Payton received an award of options to purchase 99,827 shares of common stock on October 29, 2026, at an exercise price of $20 per share. One quarter vests on July 28, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to her continued service on each vesting date.

Insider Trade Summary

Grant/Award: 99,827 shares

Grant/Award 1 txn

Insider Payton Lori

Role Chief Development Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	99,827	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 99,827 contracts (Direct)

Footnotes (1)

1. F1. This option represents a right to purchase 99,827 shares of the Issuer's common stock, one quarter of which will vest on July 28, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Key Figures

Option award: 99,827 options Underlying shares: 99,827 shares Exercise price: $20 per share +2 more

5 metrics

Option award 99,827 options Granted October 29, 2026

Underlying shares 99,827 shares Shares the options represent the right to purchase

Exercise price $20 per share For the options granted October 29, 2026

First vesting date July 28, 2027 One quarter of the options vests on this date, subject to continued service

Expiration date October 29, 2036 Option award

Key Terms

Stock Option (Right to Buy), vesting, equal monthly installments, continued service

4 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

vesting financial

"remaining three quarters vesting in equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

equal monthly installments financial

"vesting in equal monthly installments"

continued service technical

"subject to the Reporting Person's continued service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many options did YARW's Chief Development Officer receive?

Lori Payton, Yarrow Bioscience's Chief Development Officer, received options representing the right to purchase 99,827 shares of common stock at an exercise price of $20 per share on October 29, 2026. The reported resulting option position was 99,827 options.

When do Lori Payton's YARW options expire?

The options expire on October 29, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Payton Lori

(Last) (First) (Middle)

C/O YARROW BIOSCIENCE, INC.

470 JAMES STREET, SUITE 007

(Street)

NEW HAVEN CONNECTICUT 06513

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Yarrow Bioscience, Inc. [ YARW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$20	10/29/2026		A		99,827		(1)	10/29/2036	Common Stock	99,827	$0	99,827	D

Explanation of Responses:

1. This option represents a right to purchase 99,827 shares of the Issuer's common stock, one quarter of which will vest on July 28, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Tyler Zeronda, as attorney-in-fact for Lori Payton	10/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)